April 12, 2016April 19, 2016

Quinsair Inhaled Therapy for Cystic Fibrosis Is Launched in Europe, Raptor Announces

Cystic Fibrosis, News

Raptor Pharmaceutical Corp. announced its first commercial sale of Quinsair, a levofloxacin inhalation solution, in Germany and Denmark. The European Union (EU) and Canada have already approved Quinsair for the management of ... Read more

March 22, 2016May 13, 2016

FDA Designation to Speed Testing of Inhaled Antibiotic, Levofloxacin, to Treat Lung Infections

Bronchiectasis, Cystic Fibrosis, News

Raptor Pharmaceutical Corp. announced that its proprietary inhaled levofloxacin, MP-376, has been given Qualified Infectious Disease Product (QIDP) designation by the U.S. Food and Drug Administration (FDA) to treat three specific indications: ... Read more